# A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine

> **NCT01302067** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 2012 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Fesoterodine 8mg
- **DRUG:** Fesoterodine 4mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01302067
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 2012 (ACTUAL)
- **Last updated:** 2014-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01302067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01302067, "A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01302067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*